Phase 1b Trial Evaluating Idelalisib in Children and Adolescents With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Mediastinal B-cell Lymphoma in Combination With RICE
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 30 Jan 2019
At a glance
- Drugs Idelalisib (Primary) ; Carboplatin; Etoposide; Ifosfamide; Rituximab
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Mediastinal disorders
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 25 Jan 2019 This study has been discontinued in Spain.
- 07 Dec 2018 Status changed from recruiting to withdrawn prior to enrolment.
- 31 Aug 2018 Biomarkers information updated